Fn Beta News Today

New research supports the use of highly effective therapies as first-line treatment in children with relapsing-remitting pediatric-onset multiple sclerosis.

Analogous to the early 2000s when treatment options for psoriasis jumped, the same may be true now for treating cutaneous autoimmune disorders.

Damaged mitochondrial DNA initiates and spreads Parkinsons disease pathology, potentially opening new avenues for early diagnosis, researchers say.

Response rates in a phase 2 trial of a novel therapy for skin-predominant dermatomyositis were favorable in patients failed by at least one prior standard therapy, prompting plans for a phase 3 trial.

Since the emergence of the first therapy, more than 20 agents with moderate to high efficacy have come to market for relapsing multiple sclerosis – but experts say thats both a blessing and problem.